Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Maybe you can also pay attention to our smart microplate reader
- Featured-Product
ELISA Kit for Vascular Endothelial Growth Factor 121 (VEGF121)
- Product No.SEB851Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range15.6-1,000pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 6.3pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 312
US$ 445
US$ 2003
US$ 3783
US$ 31150
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Vascular Endothelial Growth Factor 121 (VEGF121).
No significant cross-reactivity or interference between Vascular Endothelial Growth Factor 121 (VEGF121) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor 121 (VEGF121) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor 121 (VEGF121) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 88-102 | 93 |
| EDTA plasma(n=5) | 78-88 | 84 |
| heparin plasma(n=5) | 91-105 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor 121 (VEGF121) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor 121 (VEGF121) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor 121 (VEGF121) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-92% | 85-101% | 90-99% | 92-105% |
| EDTA plasma(n=5) | 90-97% | 80-94% | 84-94% | 98-105% |
| heparin plasma(n=5) | 96-104% | 80-101% | 99-105% | 86-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Oncogene | Elevated PLGF contributes to small-cell lung cancer brain metastasis PubMed: 22797069 |
| BMC Cancer | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma Pubmed:29747600 |
| JOURNAL OF CLINICAL NEUROSCIENCE | A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment Pubmed: 33222957 |
| INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE | Associations between VEGF isoforms and impending retinopathy of prematurity Pubmed: 32737903 |
| international journal of oncology | Activin A triggers angiogenesis via regulation of VEGFA and its overexpression is associated with poor prognosis of oral squamous cell carcinoma Pubmed: 32377747 |